Treatment of extended spectrum betalactamases producing bacteria;Terapia de bacterias productoras de β-lactamasas de espectro extendido

Revista Chilena de Infectologia

Volumn 20, Issue SUPPL. 1, 2003, Pages

  Morales I, Ricardo ^a  

^a HOSPITAL BARROS LUCO TRUDEAU   (Chile)

Author keywords

Carbapenems; Cefepime; Enteobacteriaceas; Extended specrum beta lactamases; Treatment

Indexed keywords

EID: 55449118601     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Rupp M E, Fey P D. Extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003; 63(4): 353-65.
2. Paterson D L, Ko W C, Von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparent susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microb 2001; 39(6): 2206-12. Review.
3. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically ; Approved Standard- Sixth Edition. M7A6, Vol 23 (2): 12.
4. Medeiros A A, Crellin J. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula. Pediatr Infect Dis J 1997; 16(3 Suppl): S49-55.
5. Rahal J J, Urban C, Horn D et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998 Oct 14; 280(14): 1233-7.
6. Pirota L, Aubé H, Doise J M, Vincent-Marti M. Spreed of extended-epectrum beta-lactamase-producing Klebsiella pneumoniae: Are Beta-Lactamase Inhibitors of therapeutic value?. Clin Infect Dis 1998; 27: 76-80.
7. Pena C, Pujol M, Ardanuy C et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42(1): 53-8.
8. Thomson K S, Moland E S. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001 Dec; 45(12): 3548-54.
9. Bradford P A. Extended-spectrum beta-lactamases in the 21th century: characterization, epidemiology, and detection of this resistance threat. Clin Microbiol Rev 2001; 14(4): 933-51.
10. 10.- Patterson J E, Hardin T C, Kelly C A, García R C, Jorgensen J H. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000; 21(7): 455-8.
11. 11.- Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G; Italian ESBL Study Group. Occurrence of extended-spectrum beta-lactamases in members of the family Enterbacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002; 46(1): 196-202.
12. 12.- Paterson D L, Mulazimoglu L, Casellas J M et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30(3): 473-8.
13. 13.- Martínez-Martínez L, Hernández-Alles S, Alberti S, Tomas JM, Benedi VJ, Jacoby GA. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins. Antimicrob Agents Chemother 1996; 40(2): 342-8.
14. 14.- Pangon B, Bizet C, Bure A, Pichon F, Philippon A, Regnier B, and Gutmann L. In vivo selection of cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis 1989; 159: 1005-6.
15. 15.- Bradford P A, Urban C, Mariano N, Projan S J, Rahal J J; Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother 1997 Mar; 41(3): 563-9
16. 16.- Ambrose P G, Bhavnani S M, Jones R N. Pharmacokinetics- pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003; 47(5): 1643-6.
17. th ICAAC Chicago, December 16-19, 2001 Abstract K 1180.
18. 18.- Meyer K S, Urban C, Eagan J A, Berger B J, Rahal J J. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993 1; 119(5): 353-8.
19. th ICAAC 1997, Toronto Sept 28-Oct 1 Abstract J-210.
20. 20.- Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, β-lactamase-producing Escherichia coli and Klebsiella pneumoniae Pharmacother 2001; 21: 583-92.
21. 21.- Mell S, Zemelman C, Bello H, Domínguez M, González G, Zemelman R. Propiedades microbiológicas, clasificación y relación estructura-actividad de cefalosporinas e importancia de las cefalosporinas de cuarta generation. Rev Chil Infect 2001; 18(1): 7-19.
22. 22.- Cunha B. Ertapenem: a review of its microbiologic, pharmacokinetic and clinical aspects. Drugs Today 2002, 38(3): 195-213.